Investing

Pfizer PFE Stock News

Pfizer (NYSE: PFE)

Pfizer has been a very interesting stock to follow this year. While the stock didn’t see much growth throughout the year 2014, that hasn’t necessarily been the case for 2014 as investors have been excited about the big moves the company is making toward growth. For example, Monday and Tuesday, the company made two different announcements; both of them being filled with incredibly good news. Today, we’ll talk about the two announcements in detail, what we’ve seen from Pfizer so far this year, and what we can expect from the company throughout the rest of the year. So, let’s get right to it…

Monday’s Announcement: Pfizer To Acquire Two Vaccines From GlaxoSmithKline

On Monday, Pfizer announced that it had agreed to acquire two vaccines from GlaxoSmithKline for a total price of roughly $130 million. The vaccines being acquired are designed for vaccination against meningitis and are a clear move for PFE to expand global reach with regard to preventing meningococcal disease. The vaccines, both single dose, include…

  • Nimenrix – Nimenrix was first launched three years ago and is currently avaialable for sale in 61 countries outside of the United States.
  • Mencevax – Mencevax is currently approved in 79 countries outside of the United States and is currently used for travelers that visit countries where meningitis is a major concern.

These acquisitions are the latest break in Pfizer’s goal of reducing and controllin meningitis around the world. However, they aren’t the only moves that the company has made. As a matter of fact, just last year, PFE acquired Baxter International’s meningitis vaccine known as NeisVac-C.

Teusday’s Announcement: Pfizer Enrolled Its First Patient In The RESET Phase 3 Study

On Tuesday, Pfizer made another big announcement. The company had announced that it has enrolled its first patient in the RESET study. RESET or Rivipansel: Evaluating Safety, Efficacy and Time to Discharge, is a Phase 3 study that looks into the safety and efficacy of rivipansel for the treatment of vasco-occlusive crisis in hospitalized individuals with sickle cell disease over the age of six years. Upon the announcement of the study enrollment, Sonja L. Banks, CEO of Pfizer had the following to say…

Scientific innovation cannot forge ahead without the patients that are willing to work with the scientific community by participating in clinical trials…Patients should speak with their healthcare providers if they are interested in learning more about how to participate in the trial.”

As mentioned above, the RESET trial is a phase 3 study. The trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study with a goal of enrolling at least 350 patients that suffer with sickle cell disease and are age six or older.

How The Market Reacted To The News

Unfortunately, the market didn’t have the reaction one would generally expect to these announcements. While there was slight growth in the stock on both Monday and Tuesday, PFE trended downward throughout the rest of the week. Currently, PFE is trading at $33.96 per share; hovering just below support.

What We’re Likely To See From PFE Moving Forward

Moving forward, I’m expecting overwhelmingly positive news in both the short and long term outlook. Here’s how I see it…

  • Short Term – In the short term, the most important thing to look at is technical data. From a technical standpoint, PFE looks like it’s ready to start moving up again. Over the past month, PFE has found support at $33.98. However, on Friday, the stock fell to $33.96; where it closed the day. At this point, it’s highly likely lat $33.96 will be the new level of support and that PFE will start climbing from here.

  • Long Term – In the long term, I’m also expecting to see bullish movements from PFE. The bottom line is that this company has a constant focus on creating better and better treatments for rare and debilitating diseases. Whether it be through an acquisition or in house innovation; their goal is to find or create treatments that prove to be effective for the masses. With strong management and a strong team of doctors and scientists, as well as a plan and a willingness to follow through, I simply couldn’t think of a scenario where this stock is likely to fall long term.

What Do You Think?

Where do you think PFE is headed and why? Let us know in the comments below!

Image Credit

I’m going to briefly discuss Betterment, a new option in the investment market. More detailed analysis of all the great things Betterment has to offer is available over at Modest Money. For now we’ll cover the basics of Betterments “set it and forget it” approach or, in the words of their CEO, “what you should be doing”.

Betterment has been around since 2008, but has made a lot of headway in the investment marketplace in this time. In short, Betterment is an “online financial advisor that provides optimized investment returns for individual, IRA, Roth IRA & rollover 401(k) accounts”. Recommended for investors with $10,000 to $10,000,000 to put in, Betterment has put together packages of diversified ETFs to provide maximum maximum returns and minimal risk for its customers. There is no tinkering required on your part.

Because Betterment can manage your money with little or no input on your part, their model has been described as fully automated. This is a great option for busy people or those without decades of experience in the investment world. They make an emphasis on design and usability, so that with a free Betterment account, you’ll be able to interact with your financial information with intuitive and accurate graphical representations. Because of the simplicity of use and the high returns they offer, Betterment is a great option for newer or first time investors, particularly those without huge amounts of riches to invest.

Once you’ve signed up and your money is in their hands, your funds will be invested into 6 varied stock EFTs: 25% Vanguard Total Stock Market, 25% iShares S&P 500 Value Index, 25% Vanguard Europe Pacific, 10% Vanguard Emerging Markets, 8% iShares Russell Midcap Value Index, and 7% iShares Russell 2000 Value Index. With bonds, your funds will be split evenly between iShares Barclays TIPS Bond Fund and iShares Barclays 1-3 Year Treasury Bond FUN. Betterment gives you the benefit of a intelligently diversified investment portfolio automatically. If you lack the expertise to organize and optimal portfolio on your own, or if you fear your own tendency to overly involve yourself, Betterment gives you exactly what you need.

Since you aren’t intimately involved in the gory details of your investments, what involvement do you have? This is where Betterment’s design prowess really shines, more so than much of the competition. With your free account you get your own Dashboard, a visual representation of exactly how your money is doing. You’ll be able to set up specific financial goals. Betterment will automatically show you exactly what you will have to do to meet those goals within certain time limits. Betterment costs slightly more than similar market options, but the level of investment security they provide is worth it. You’ll see your initial investment grow predictably and reliably over time. Betterment is built to provide this service without all the guesswork that other options leave you with.

Betterment is one of the best options on the market for new investors, particularly those with new or modest investment capital. Learn more about how Betterment can change your financial life for the better with security and reliability. For a detailed review and an exclusive interview with Betterment’s CEO Jon Stein, check out the Betterment review on Modest Money.

Tech Stock To Watch Closely

The tech sector is relatively mixed today. However, there are several opportunities for growth; especially with some of the big guys that are declining today. Here are a few opportunities in tech that I’ve been able to dig up…

Facebook Stock Is Down, But Not For Long

Facebook Inc (NASDAQ: FB)

Facebook has been an incredibly fun stock to watch recently. As the stock continues to gain, FB’s market capitalization is nearing $245 billion; making it one of the top 10 largest companies in the world. Now, the big question is, can it continue to grow? In my opinion, we’ve only seen the beginning. When we talk about Facebook, we’re talking about a social network that’s outgrown its sector. After all, Facebook is no longer a social network; it’s in a category of its own. The company has ingrained itself in the day to day life of the average consumer; and continues to focus on ways to earn more profit from doing so. In the long run, I’m expecting to see more big gains from FB. Considering the fact that the stock is slightly down today, there’s a big opportunity for those that want to get in on the gains!

BlackBerry Stock Is Headed For Big Reversal

BlackBerry Ltd (NASDAQ: BBRY)

BlackBerry hasn’t had the best time in the market recently. After more than a month of climbing, the value of the stock saw a reversal on May 11th; starting a downtrend that has lasted to this day. However, I think that there’s another reversal just around the corner; and this time it’s moving in the positive direction. BBRY recently announced that they are planning to buy back 12 million shares. The goal here is to help dial down dilution in the shares thanks to the employee stock plans. As a result, the stock will most likely increase as supply dwindles and demand rises. So, keep a close eye here; when the uptrend starts, it’s likely to continue for some time!

Ambarella Stock Starts To Rebound…Get Ready For Big Gains

Ambarella Inc (NASDAQ: AMBA)

Last week, a firm known for short-selling, Citron Research released a report on AMBA that sent the stock tanking; stating that the stock was “ridiculous” and insinuating major downside risk. However, Ambarella stock is recovering today as Jim Cramer weighs in with a much more positive opinion. In a recent announcement, Cramer stated that the video-capture chip maker is one of only a handful of companies with accelerating revenue growth and that the stock deserves a premium valuation considering the fact that it is expected to see a 55% growth in revenue in 2016. Today, investors seem to be siding with Cramer; sending AMBA on uptrends that I don’t think are going to stop any time soon. So, keep your eye out for dips because they are likely to prove to be great buying ops.

MeetMe Stock Climbs On Increased Guidance

MeetMe Inc (NASDAQ: MEET)

MeetMe, the emerging social network is up in the market today after announcing that it expects to report higher revenue than previously estimated in the second quarter. The guidance before insinuated revenue to come in at between $9 million and $9.5 million for the quarter. However, new guidance raises the expectations to between $10.5 and $10.7 million; and investors are loving the news. Considering the new guidance, this stock is likely to see gains for some time. So, watch for dips as they will likely be great buying opportunities.

Do You Know Of Any Others?

Do you know of any other stocks in tech that are presenting opportunities? If so, let us know in the comments below!

Image Credit

Service Sector Stocks To Watch AMZN BBRY NFLX DIS

In the service industry, I believe that there are a few stocks that are presenting very strong opportunities. With that said, below are my favorites in service and why you should be watching these stocks…

Netflix Continues Declining On Icahn Announcement

Netflix, Inc. (NASDAQ: NFLX)

Netflix had a great run on Wednesday after announcing that the company would be performing a 7-1 stock split; meaning that if you own 1 share now, you will own 7 shares of the company after the split. This caused big gains. However, yesterday, billionaire Carl Icahn announced in a Twitter post that he had sold the remaining shares he had in the company; stating that Apple currently provides a better opportunity. While I agree with Icahn, I think it’s important not to discount the opportunity that Netflix provides; and thanks to the declines we saw yesterday and today, the stock is even more appealing. That’s because after the split, more investors will have access to the new, lower priced shares. This will likely cause the stock to gain in value as demand for shares increases. So, with regard to Netflix, it may be time to start looking for support as this one is likely to see pretty big gains relatively soon!

Amazon Web Services Is Getting Quite A Bit Of Attention

Amazon.com, Inc. (NASDAQ: AMZN)

Amazon is another stock that’s well worth watching closely. While I started to lose my faith in the stock last year, this year has been great; and is likely to get better. A few months ago, AMZN gave us a look into the details of Amazon Web Service, a cloud service offered by the company. At the time, AWS had already grown to be a $5 billion per year business; and margins are great since overhead on the service is incredibly low. As a result, their stock has been on a steep uptrend for quite some time now; leading analysts like Axiom to weigh in with upgraded ratings. With that said, I’m expecting AWS to continue to drive AMZN higher. So, if you’re looking for an opportunity for gains, this may just be what you’re looking for.

Walt Disney Stock Continues An Uptrend That’s Not Likely To Reverse

Walt Disney Co (NYSE: DIS)

Walt Disney stock is definitely one for the longs. The reality is that since its entrance in the market in 1978, we’ve seen uptrends leading to more uptrends; with the only major declines happening around poor economic times. With that said, if you’re looking for a solid long term investment, DIS is a very strong option. All you’ll need to do is look for the occasional pull back for your opportunity to get in on the gains!

BlackBerry Stock Is Likely To See A Trend Reversal

BlackBerry Ltd (NASDAQ: BBRY)

BlackBerry has had a rough time in the market recently. For more than a month, its stock price has been rolling down the hill. However, I think that this trend is likely to see a reversal relatively soon. BlackBerry announced today that it is planning a 12 million share buy back program. The goal here is to offset share dilution from employee stock plans. Ultimately, the buy back will make supply of BBRY shares fall; hopefully leading to an increase in demand and it’s price per share. So, this is another stock to watch closely for dips and buying ops as gains seem to be just around the corner.

Do You Know Of Any Others?

Are you watching any stocks in the service sector that are presenting strong opportunities? If so, let us know what they are in the comments below!

Image Credit

Synergy Pharmaceuticals Stock News

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals has been a hot topic in biotech recently after gaining massively toward the end of last week. However, since the gains, we’ve seen slow and steady downtrends; leading investors to ask… “Can SGYP edge up any higher?” In my opinion, the answer is yes! Not only can the stock rise higher, it will; we just have to give it some time. Today, we’ll talk about what caused the gains we saw last week, what I believe is causing the declines this week, and what we can expect to see from the stock moving forward. So, let’s get right to it.

What Caused Synergy Pharmaceuticals To Climb?

Last week, Synergy Pharmaceuticals stock saw massive gains after the release of new data surrounding plecanatide. Plecanatide is an experimental drug designed to treat those with irritable bowel syndrome with constipation (IBS-C). The recent data from the Phase 3 study showed that not only was the drug effective in treating the condition, it produced less side effects than the current market leader. Linzess, the current market leader, causes diarrhea in about 16% of those who use it. However, plecanatide causes diarrhea in only about 6% according to the study results. Following the positive news, investors naturally pushed the stock higher.

What’s Causing The Decline

When it comes to the declines we’ve seen this week, it’s not hard to pinpoint a reason. When looking at the market, it’s clear to see that after a stock experiences massive increases in value, it’s not uncommon to see declines following the rally; it’s nothing more than normal market movement. When trading, it’s important to remember that price movement in the market is a series of overreactions. So, in this particular case, positive data caused investor excitement; sending the value of the stock up in a big way. However, the excitement caused the stock to grow too much, too fast. As a result, we’ve seen a bit of a correction this week. However, that doesn’t mean that SGYP doesn’t still have room to grow. As a matter of fact, I think this stock has massive upside potential.

What We Can Expect From SGYP Moving Forward

Moving forward, I’m expecting overwhelmingly positive news from SGYP in both the short term and long term outlooks. Here’s what I’m expecting to see happen.

Short Term – In the short term, we’re likely to continue to see more declines throughout the rest of today, and possibly tomorrow. However, I think the story is going to be quite different next week. The current support level in the stock is a bit shaky; ranging from $8 to $7.96; and I wouldn’t be surprised if it fell to the $7.92 range. However, after sticking by support for a short while, I’m expecting to see big gains. With that said, we’re likely to start seeing growth either Friday or Monday.

Long Term – In the long run, I maintain my bullish opinion of Synergy Pharmaceuticals as I think this stock will produce massive gains. The reality is that Synergy Pharmaceuticals is getting closer and closer to FDA approval with plecanatide. This will prove to be profitable in the long run. Also, with strong management, and a strong team, I’d imagine that there’s plenty more good news coming down the pipeline in the long run. So, watch for dips and get ready for gains!

What Do You Think?

Where do you think SGYP is headed and why? Let us know in the comments below!

Image Credit

Biotech Stocks That Are Bulls

Today has been a good day for the biotech market so far. However, there are always a few stocks that far outpace the rest. I’ve dug up four of them. Here’s what’s happening and what we can expect to see moving forward…

Cleveland BioLabs Climbs On Private Placement Agreement

Cleveland BioLabs, Inc. (NASDAQ: CBLI)

Cleveland BioLabs is having a great day in the market today after the company announced that it has entered into a securities purchase agreement with David Davidovich. Davidovich, a venture capital investor, has agreed to purchase 6,459,948 unregistered shares of common stock in the company at a price of $25 million, or $3.87 per share. As a result of the agreement, CBLI has skyrocketed in the market. Currently (11:28), the stock is trading at $6.74 per share after a gain of 138.16%. Keep a close eye on this one as we are likely to see big pull backs coming soon. However, after the pull backs, we’re likely to see gains; so the dips will most likely be solid buying opportunities.

Transition Therapeutics Stock Bounces Back From Support

Transition Therapeutics Inc (USA) (NASDAQ: TTHI)

Transition Therapeutics stock fell dramatically yesterday after announcing that its Phase 2/3 study into its neuropsychiatric drug candidate ELDN005 missed its primary efficacy endpoint. In the study, ELDN005 and the placebo had relatively similar effects. As a result we saw the stock decline by more than 70% in a single day yesterday. However, today, it seems as though the stock has met support and is starting to somewhat recovery. Currently (11:34), TTHI is trading at $2.47 per share after a gain of 5.11% so far today. Nonetheless, after yesterday’s dramatic climb, we’ll likely see more short term gains as the stock recovers.

RXi Pharmaceuticals Continues Climbing On New Patents

RXi Pharmaceuticals Corp (NASDAQ: RXII)

On June 9th, RXII announced that two new key patents were given to the company for use with their self-delivering sd-rxRNA technology platform. Since then, the stock has been on a relatively strong uptrend as investors remain excited about the news. Currently (11:41), RXII is trading at $0.58 per share after a gain of 11.24% so far today. Given the reason for the climb, I’d imagine that this one is going to continue for quite a while. So, look for pull-backs as buying ops.

Rockwell Medical Continues To Climb On Oppenheimer Comments

Rockwell Medical Inc (NASDAQ: RMTI)

Finally, Rockwell Medical stock continues to climb following Oppenheimer’s bullish comments on the stock. Oppenheimer recently had a meeting with management at Rockwell Medical; reiterating an outperform rating and strong target price on the stock after the meeting. This is another that is likely to climb for quite a while. So, keep an eye out for pull-backs as they will likely prove to be great buying opportunities.

Do You Know Of Any Others?

Do you know of any other big gainers in biotech? If so, let us know in the comments below!

Image Credit

Biotech Stock Bulls

Today hasn’t been the best day for US stocks; especially in the biotech space. Unfortunately, when looking at the biotech sector, we’re seeing a sea of red. However, there are a few stocks that are doing well regardless of today’s conditions in the market. Here are some of the biggest gainers in biotech today and what we can expect from them moving forward…

Synergy Pharmaceuticals Stock Is Moving Up Again!

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals stock had a relatively rough start to the week this week in the market. After climbing dramatically last week on the release of plecanatide data, we saw a bit of a correction on Monday and Tuesday. However, today we’ve seen another reversal as the stock has finally reached support. Earlier today, it was up more than 6%; however currently (1:34), SGYP is trading at $8.35 per share after a gain of 2.83% so far today. Nonetheless, I’m expecting to see more gains in the future. The reality is that there’s a good reason for growth on the stock; plecanatide is likely to become incredibly profitable in the future. So, keep your eye out for pull backs and buying opportunities if you’d like to get in on the growth.

Catalyst Pharmaceutical Partners (CPRX) Stock Climbs On TD Study Data

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX)

Catalyst Pharmaceutical Partners stock is climbing today following the release of top-line data from their most recent study into an experimental treatment for Tourette’s Disorder known as CPP-109. The study looked into the effectiveness of the compound in patients with Tourette’s Disorder for whom other treatments didn’t prove to be effective. The data released showed that CPP-109 was able to reduce ticks by about 25%, but had now affect on the underlying condition causing the ticks. Nonetheless, the company remains optimistic and will use the data to continue working to find a way to treat the ailment. All in all, the data was positive and investors are happy. As a result, CPRX is currently (1:40) trading at $4.07 per share after a gain of 2.03% so far today; and is likely to keep heading in the upward direction.

Rockwell Medical Stock Is Up On High Volume

Rockwell Medical Inc (NASDAQ: RMTI)

Rockwell Medical stock is having a great day today; gaining on high volume. According to NASDAQ, the average daily volume on the stock over the past 50 days has been 620,202. However, today RMTI has traded hands 1,138,671 times. It’s my opinion that the increased volume and climb in value is the result of recent overwhelmingly bullish comments from Oppenheimer after meeting with Rockwell Medical management earlier in the week. Considering the activity we’re seeing and the reason for the activity, I’m expecting to see long term bullish trends. So, now may be the time to start looking for pull backs and entrance opportunities.

Vanda Pharmaceuticals Stock Climbs On Positive Data Release

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)

Vanda Pharmaceuticals stock is up today after a presentation in which positive results from the long-term maintenance REPRIEVE clinical study were provided. The presentation took place at the 2015 American Society of Clinical Pharmacology Annual Meeting in Florida. According to the presentation, the study demonstrated the ability of Fanapt® to prevent relaps or impending relaps in adult patients with schizophrenia. In the presentation, VNDA showed that 79.6% of patients treated with Fanapt® remained relapse free; compared to 36.6% of patients treated with the placebo. Mihael H. Polymeropoulos, MD, the CEO of VNDA had the following to say about the results…

We are delighted with the results of the REPRIEVE study presented today at the ASCP annual meeting….We believe these results underscore the potential benefits of Fanapt as a treatment alternative for adult patients living with schizophrenia.”

All in all, investors were excited about the positive news; ultimately pushing the value of VNDA up. Currently (1:55), the stock is trading at $13.60 per share after a gain of 5.42% so far today.

Nektar Therapeutics Stock Is Up On Incredibly High Volume

Nektar Therapeutics (NASDAQ: NKTR)

Finally, Nektar Therapeutics stock is up today in a big way on high volume. According to NASDAQ, the average volume on the stock over the past 50 days has been 1,643,866. However, so far today, 4,801,801 shares have traded hands; and that number is growing rapidly. It’s also important to mention that the 200 day moving average on the stock is incredibly bullish…insinuating that more gains are to come. So, keep an eye on this one for pull backs and entrance opportunities!

Do You Know Of Any Others?

Do you know of any other big gainers in biotech? If so, let us know in the comments below!

Image Credit

Gilead Sciences GILD Stock News

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead Science can tell what’s arguably the best success story in the biotech space. The company has produced the world’s leading treatments for both HIV and the hepatitis C virus; and investors seem to love the stock. As a matter of fact, GILD has been on a strong uptrend for quite some time now; leading to new record highs. However, the big question now is…can Gilead Sciences stock continue growing? In my humble opinion, the answer is yes, here’s why…

Gilead Sciences Still Controls The HCV Treatment Market

The hepatitis C virus market is huge. As a matter of fact, it’s estimated that 130 to 150 million people suffer from the condition with 300,000 to 500,000 people dying each year as a result. This is a treatment market that Gilead Sciences completely controls. Although competitors have attempted to make their names in the market, none have been as successful as GILD. For example, earlier this year, GILD saw declines in value as AbbVie Inc (NYSE: ABBV) released their own treatment for the ailment. However, AbbVie’s treatment causes far worse side effects than the GILD treatment and requires patients to take far more medications. As a result, Gilead Sciences held the crown.

GILD Is Incredibly Undervalued In The Market

Another thing that I think is very important to keep in mind is valuation. Currently, Gilead Sciences P/E ratio is at under 10. That’s incredible considering the fact that most stocks in the market have a P/E ratio of upwards of 17 right now. This means that in relation to other stocks on the market, GILD is incredibly cheap…but why?

The answer goes back to the argument above. Gilead Sciences controls the HCV market. However, AbbVie made an attempt to take their piece of the pie; and while their treatment isn’t as good as the treatment provided by GILD, they’ve done pretty well for themselves. As a result, investors became concerned that Gilead’s sales in the HCV space would decline; ultimately causing declines in the value of the stock. As a result, investors have been hesitant to push the stock up as fast as it should be going. This has led to slow, steady growth and massive under-valuations with regard to the stock.

While I do understand the concern, I think that at this point, it’s time to put this concern to rest. The reality is that even with AbbVie competing in the HCV space, Gilead Sciences has been able not only to maintain control of the market, but to increase their profits. As an investor, I’m most interested in the bottom line. While I can admit that I was concerned about ABBV at first, after reading through the Q1 earnings report from GILD, my concerns went away. The bottom line is that ABBV hasn’t even put a dent in GILD with their release of their HCV solution.

The Bottom Line

The bottom line is that Gilead Sciences grew to be a market leader for a damn good reason. When we talk about Gilead Sciences, we’re talking about a company that has several great products, an incredible team of doctors and scientists, and management that will stop at nothing to generate growth for the company and its investors. All in all, I see this stock growing exponentially over the long term.

What Do You Think?

Where do you think GILD is headed and why? Let us know in the comments below!

Image Credit

CNA Stocks MNKD SGYP CPRX

When I created CNA Finance, I decided that I would talk about upcoming catalysts, notable movements, and alpha opportunities in the market…that’s where CNA came from. So, I thought it would be a good idea to write a post every day that points out an upcoming catalyst, a stock with notable movements, and an alpha opportunity in the market. Today, that starts. So, without further ado, here’s the CNA stocks of the day…

Catalyst: MannKind Stock Will Climb On Direct-to-Consumer Campaign

MannKind Corporation (NASDAQ: MNKD)

MannKind Corporation stock has been the topic of quite the debate recently. The debate revolves around Afrezza; an inhaled insulin the company created using their proprietary technosphere technology. However, Afrezza hasn’t sold so well. Nonetheless, the reason for the low sales is the fact that the drug hasn’t actually launched yet…it’s currently in pre-launch phase. However, that’s changing soon, and when it does, it will prove to be a big catalyst for the stock. Within weeks, Afrezza will move into the Direct-to-Consumer campaign; a campaign that I believe will show the true value of the inhaled insulin and cause MNKD to climb dramatically. So, keep your eyes on this stock as it’s likely to climb very soon.

Notable Movement: Synergy Pharmaceuticals Stock Edges Back Up

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals stock enjoyed a nice climb last week as plecanatide Phase 3 data was released; showing that the drug is not only effective in treating those with irritable bowel syndrome with constipation, but it has less of a chance of causing diarrhea than the current leader in the market. However, this week hasn’t been so great for the stock. On both Monday and Tuesday, we watched as SGYP saw bearish activity in the market. However, today, that is changing as the stock breaks out. Synergy Pharmaceuticals reversed directions gaining more than 6% in early trading today. While we’re seeing a bit of a pull back at the moment, I’m expecting to see more strong growth in both the short term and long term outlooks. So, this is one that you’ll want to keep a close eye on as it will likely lead to more opportunities down the road.

Alpha Opportunity: Catalyst Pharmaceutical Partners Stock Climbs On Top-Line Data Release

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX)

Catalyst Pharmaceutical Partners stock is up today following the announcement of top-line results in an open-label, proof-of-concept trial looking into CPP-109; an experimental drug used to treat patients with Tourette’s Disorder that were refractory to all other previous treatments. The data from the study showed that patients saw a 25% reductions in tics, but did not see subjective clinical improvement. Upon the release of the data, Patrick J. McEnany, CEO of CPRX had the following to say…

We see these data as promising dispite the small number of subjects, single center, open-label design trial….These top-line results demonstrate an encouraging signal of activity in adult treatment-refractory patients with Tourette’s Disorder. We believe that CPP-109’s mechanism of action validates the potential for CPP-115 to be a candidate for the treatment of Tourette’s Disorder. We are evaluating our options and will be meeting with the Co-Principal Investigators of the trial, as well as other key opinion leaders, to determine the next steps in development.”

All in all, the positive data from the study pushed the stock up; and the gains are likely to continue. So, keep an eye out for pull-backs and buying opportunities!

Image Credit

Alfred Mann MannKind MNKD Stock News

MannKind Corporation (NASDAQ: MNKD)

If you follow my work here or elsewhere, you know that MannKind is one of my favorite stocks to follow. Aside from the debate revolving around the stock’s ability to grow, I’m intrigued by the fact that this company has come up with a way to deliver insulin to the body without an injection. If you follow the stock, you know that the debate revolving around it is a big argument with regard to whether or not Afrezza will pick MNKD up in the market. Personally, I think that the answer is yes, but that’s not the only reason I’ve got such a bullish long-term opinion on the stock. While MNKD has had a bit of a rough time recently, I’m really not concerned; and I don’t think most longs are. So today, we’ll discuss why MNKD longs aren’t concerned about declines and what we can expect from the stock moving forward. So, let’s get right to it…

Afrezza Will Be The Goose That Lays The Golden Egg For MNKD In The Long Term

One of the biggest pieces to the argument revolving around MannKind stock is Afrezza. Afrezza is an insulin that instead of being delivered to the human body through an injection, is delivered through an inhaler. This is a big move in the world of medicine and was made possible by MannKind’s proprietary technosphere technology. However, bears on the stock argue that Afrezza isn’t going to be as popular as the company hopes based on the sales seen so far. While I can understand the argument and respect the right to personal opinions, I have to disagree with this assessment.

The first thing we need to keep in mind when gauging the popularity of Afrezza is the fact that the insulin hasn’t even made it to an official launch. What we’ve seen so far has been a pre-launch; one with absolutely no advertising. So, we can’t expect to see massive sales volume. However, we can expect to see sales volume pick up relatively soon. In just a few weeks, the Direct-to-Consumer campaign for Afrezza will start; and this is when we’re likely to see sales climb!

MannKind Has So Much More To Offer In The Long Term

Another thing to keep in mind is that long investors in MNKD aren’t really concerned with what’s going on now. Instead, they’re paying close attention to the intrinsic value of the company; a value that includes far more than Afrezza. MannKind longs are confident that Afrezza won’t be the only major hit; and for good reason. The company has announced that they are working on new medications using their patented technosphere technology; and considering that there are several medications that can only be delivered through an injection, the scope of the company’s ability to change the way we see medication is relatively large! As a person that is deathly afraid of needles in the first place, this is incredibly interesting to me; and while not everyone has a fear of needles, most investors can see how using technosphere to deliver medications can be incredibly profitable.

What To Expect From MNKD Moving Forward

The bottom line is that MannKind is destined for growth. We can expect to see massive increases in the value of the stock as Afrezza moves into the Direct-to-Consumer campaign; which will happen relatively soon. Also, in the long run, MNKD is poised for growth. As a result of the lack of understanding in the product, the stock has been kept relatively low; making it a cheap way to realize long term gains. As the company continues to produce incredible medications, it will have no choice but to climb in the long run.

What Do You Think?

Where do you think MNKD is headed and why? Let us know in the comments below!

Image Credit

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 5772
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...